7.40
-0.25
(-3.27%)
As of 8:28:07 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 6 | 8 | 8 |
| Avg. Estimate | 8.93M | 29.35M | 20.51M | 98.23M |
| Low Estimate | 6M | 11.3M | 17.6M | 59.7M |
| High Estimate | 12M | 95.6M | 23.57M | 170.5M |
| Year Ago Sales | 13.22M | 3.42M | 27.46M | 20.51M |
| Sales Growth (year/est) | -32.47% | 756.89% | -25.30% | 378.82% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 1GDA.F | -- | -- | -- | -- |
| S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/20/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/14/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 10/11/2024 |
| Initiated | Guggenheim: Buy | 10/7/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 10/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/30/2024 |
Related Tickers
CVAC.VI CureVac N.V.
3.6080
-3.84%
BT3.BE Lineage Cell Therapeutics Inc
0.5850
0.00%
471A.F aTyr Pharma, Inc.
3.4200
+1.18%
2Q5.BE Enochian BioSciences Inc
0.8460
-0.24%
HQ1.MU Oruka Therapeutics Inc. R
11.80
-3.28%
PH4.F CStone Pharmaceuticals
0.2860
0.00%
ORN.F Oryzon Genomics S.A.
1.4660
+3.97%
4FR.BE Faron Pharmaceuticals Oy
2.1900
-0.90%
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.4700
-3.09%
25I.F ImmuPharma plc
0.0465
+106.67%